Home › High Blood Pressure › NCT07780500
REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension
RecruitingObservational study
REFOCUS-HTN US-WEST: a Data Infrastructure to Characterize Contemporary Individuals With Hypertension, Their Care, Health Outcomes, and Wellbeing
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: The SCALED Cohort will be identified from the REFOCUS-HTN Cohort which includes men and women ≥ 18 years of age with established hypertension in the KPNC EHR from January 2012 through March 31, 2029. Established hypertension will be defined as one of the following: * ≥1 outpatient, non-emergency department diagnosis of hypertension; * ≥2 consecutive outpatient measures of systolic blood pressure ≥130 mmHg at least 90 days apart; * ≥2 consecutive outpatient measures of diastolic blood pressure ≥80 mmHg at least 90 days apart. Additional Eligibility Criteria for SCALED: * Hypertension diagnosis within the past 18 months prior to screening. * At least 6 months of continuous health plan coverage prior to initial visit. Exclusion Criteria: * Diagnosed cause of secondary hypertension from drug or alcohol induced, or renovascular hypertension; * Bariatric surgery or GLP1 prescription in the last 12 months; * Exposure to an aldosterone synthase inhibitor or a mineralocorticoid receptor antagonist in the last 12 weeks; * Last known estimated glomerular filtration rate \< 45 mL/min/1.73m2 (according to the CKD-EPI equation) at the time of screening; * Kidney transplant; * Currently receiving dialysis; * Current enrollment in any cardiovascular or blood pressure interventional trial.
About the study
The goal of the REFOCUS-HTN US-WEST program is to gain a better understanding of the role of a hormone called aldosterone in the development of hypertension. The SCALED sub-study is an observational cohort study that will enroll from REFOCUS-HTN cohort for prospective data collection.
What is being tested
- observational study (other)
Sponsor: Kaiser Permanente · Participants: 500 · Started: Aug 20, 2026
Contact the study team
- Ankeet S Bhatt, MD, MBA, ScM · Phone: 415-470-6571
- Mirasol M Apostol-Largeteau, MPH · Phone: 415-407-1754
Official record on ClinicalTrials.gov — NCT07780500
Locations in the U.S.
| California | Kaiser Permanente Northern California, Oakland |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.